PTLA’s phase-3 Betrixaban trial has to hit p<0.01 to be deemed a success as the sole phase-3 trial in the program, according to today’s BioCentury webcast.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”